首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1630636

男性乳癌治療市場規模、佔有率、成長分析、按類型、按產品類型、按治療、按診斷、按最終用戶、按地區 - 行業預測，2025 年至 2032 年

Male Breast Cancer Treatment Market Size, Share, Growth Analysis, By Type, By Product Type, By Treatment, By Diagnosis, By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年01月07日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球男性乳癌治療市場規模價值 44 億美元，預計將從 2024 年的 45.6 億美元成長到 2032 年的 61 億美元，預測期間（2025-2032 年）的複合年成長率為 3.7%。

儘管男性乳癌很少見，但它已成為一個嚴重的問題，尤其是在人口老化和肥胖率上升的背景下。這種癌症是由乳腺組織細胞快速分裂引起的，通常與 BRCA2 等基因突變有關，主要影響老年男性，一生中患病風險為 1/833。有趣的是，它佔所有癌症的不到 1%。然而，隨著認知的提高、早期診斷和有效治療方案的出現，存活率正在提高。主要的市場促進因素包括癌症患者數量的增加和生物技術的進步，百時美施貴寶和克洛維斯腫瘤學公司的合作證明了這一點。然而，高昂的研究成本和缺乏一致的治療策略等挑戰仍然存在，這可能會阻礙市場成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前 5 家公司對比
主要企業市場定位（2024年）
主要市場參與者所採用的策略
近期市場趨勢
公司市場佔有率分析（2024 年）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分析市場佔有率
- 收益與前一年同期比較（2022-2024 年）

主要企業簡介

Pfizer Inc.（USA）
Johnson & Johnson（USA）
Novartis AG（Switzerland）
Roche Holding AG（Switzerland）
GlaxoSmithKline plc（UK）
Sanofi SA（France）
Bayer AG（Germany）
Bristol-Myers Squibb Company（USA）
Eli Lilly and Company（USA）
AstraZeneca plc（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
Sun Pharmaceutical Industries Ltd.（India）
BioNumerik Pharmaceuticals, Inc.（USA）
Seattle Genetics, Inc.（USA）
Accord Healthcare Ltd.（UK）
Merck & Co., Inc.（USA）
Fresenius SE & Co. KGaA（Germany）
Mylan NV（USA）
AbbVie Inc.（USA）
Amgen Inc.（USA）

結論和建議

簡介目錄

Product Code: SQMIG35D2234

Global Male Breast Cancer Treatment Market size was valued at USD 4.4 billion in 2023 and is poised to grow from USD 4.56 billion in 2024 to USD 6.1 billion by 2032, growing at a CAGR of 3.7% during the forecast period (2025-2032).

Male breast cancer, although rare, is emerging as a significant concern, particularly as the population ages and obesity rates rise. This cancer type arises from rapid cell division in breast tissue, often linked to genetic mutations such as BRCA2, predominantly affecting older men, with 1 in 833 at risk over their lifetime. Interestingly, it accounts for less than 1% of all cancers. However, increased awareness has improved survival rates through early diagnosis and effective treatment options. Key market drivers include a rise in cancer cases and advancements in biotechnology, as evidenced by collaborations like that of Bristol-Myers Squibb and Clovis Oncology. However, challenges remain, such as the high cost of research and the lack of a cohesive treatment strategy, which may hinder market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Male Breast Cancer Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Male Breast Cancer Treatment Market Segmental Analysis

Global Male Breast Cancer Treatment Market is segmented by Type, Product Type, Treatment, Diagnosis, End User and region. Based on Type, the market is segmented into Ductal Carcinoma in Situ, Paget's Disease of the Nipple, Inflammatory Breast Cancer, Infiltrating Ductal carcinoma and Others. Based on Product Type, the market is segmented into Chemotherapy, Medication and Others. Based on Treatment, the market is segmented into Local Treatments, Radiation Therapy, Targeted Therapy and Systemic Treatments. Based on Diagnosis, the market is segmented into Mammography, Biopsy, Fine Needle Aspiration Biopsy, Core Biopsy, Excisional Biopsy, PET Scan, CT Scan, MRI Scan and Other Tests. Based on End User, the market is segmented into Hospitals, Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Male Breast Cancer Treatment Market

The global market for male breast cancer treatment is significantly driven by rising awareness and enhanced early detection efforts. Initiatives and campaigns aimed at educating the public have played a crucial role in promoting the importance of recognizing the signs of male breast cancer, leading to timely diagnoses. Early detection is fundamental to improving survival rates and treatment success, as it enables healthcare providers to initiate appropriate therapies sooner. Furthermore, advancements in diagnostic technologies and the implementation of comprehensive screening programs have contributed to better patient outcomes, underscoring the critical importance of awareness in combating this rare condition.

Restraints in the Global Male Breast Cancer Treatment Market

The Global Male Breast Cancer Treatment market faces significant restraints due to the limited number of clinical trials and research focused specifically on male patients. This is largely because male breast cancer is rarer than female breast cancer, resulting in insufficient gender-specific research to inform treatment protocols. Consequently, treatment options may be based primarily on data derived from studies primarily involving women, which may not effectively address the unique needs of male patients. This scarcity of targeted research creates challenges in formulating optimal care plans and can potentially compromise the effectiveness of treatments intended for men diagnosed with breast cancer.

Market Trends of the Global Male Breast Cancer Treatment Market

The Global Male Breast Cancer Treatment market is experiencing a significant transformation driven by rising awareness and the evolving oncology landscape. Historically overshadowed by female breast cancer, the increasing recognition of male breast cancer has prompted dedicated research and development initiatives. Notably, a surge in male breast cancer cases has catalyzed the medical community to allocate resources towards specialized treatments and innovative therapies. This paradigm shift is fostering collaboration among researchers, clinicians, and advocates, culminating in enhanced early detection, personalized treatment options, and improved outcomes for affected men. The market is poised for growth as it increasingly focuses on addressing this unique patient demographic.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Male Breast Cancer Treatment Market Size by Type & CAGR (2025-2032)

Market Overview
Ductal Carcinoma in Situ
Paget's Disease of the Nipple
Inflammatory Breast Cancer
Infiltrating Ductal carcinoma
Others

Global Male Breast Cancer Treatment Market Size by Product Type & CAGR (2025-2032)

Market Overview
Chemotherapy
Medication
Others

Global Male Breast Cancer Treatment Market Size by Treatment & CAGR (2025-2032)

Market Overview
Local Treatments
Radiation Therapy
Targeted Therapy
Systemic Treatments

Global Male Breast Cancer Treatment Market Size by Diagnosis & CAGR (2025-2032)

Market Overview
Mammography
Biopsy
Fine Needle Aspiration Biopsy
Core Biopsy
Excisional Biopsy
PET Scan
CT Scan
MRI Scan
Other Tests

Global Male Breast Cancer Treatment Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Clinics
Others

Global Male Breast Cancer Treatment Market Size & CAGR (2025-2032)

North America (Type, Product Type, Treatment, Diagnosis, End User)
- US
- Canada
Europe (Type, Product Type, Treatment, Diagnosis, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Product Type, Treatment, Diagnosis, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Product Type, Treatment, Diagnosis, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Product Type, Treatment, Diagnosis, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNumerik Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seattle Genetics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Accord Healthcare Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments